Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 12, 2010

NextWave and Tris Enter into CNS Disease-Related Agreement

  • NextWave Pharmaceuticals and Tris Pharma are working together to enhance NextWave's CNS disease products with Tris’ drug-delivery technology for liquid and solid formulations. Additionally, Tris has reacquired the rights to non-CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

    NextWave will commercialize Nexiclon™ (Clonidine) XR Extended-Release Tablets and Suspension, a 24-hour liquid extended-release product approved by the FDA; Clonidine is used to treat hypertension. The new version will be introduced to wholesalers and pharmacies later this year. NextWave and Tris will also collaborate on the development of three additional CNS products, with an option to expand development to additional products.

    All products under the agreement incorporate Tris' OralXR+ technology for delivery of suspension or solid-dosage forms, which provides up to a 24-hour delivery profile in taste-neutral formulations.

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »